L3VLUP
ProSign in

MDT · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MDTVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MDT
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterMDTVRTX
Q3 202032 holders, $18.3bn31 holders, $21.9bn
Q4 202033 holders, $20.0bn30 holders, $18.4bn
Q1 202137 holders, $20.8bn31 holders, $15.4bn
Q2 202134 holders, $22.1bn30 holders, $12.7bn
Q3 202132 holders, $21.6bn35 holders, $10.1bn
Q4 202131 holders, $18.5bn28 holders, $12.4bn
Q1 202228 holders, $18.0bn23 holders, $16.1bn
Q2 202235 holders, $15.2bn25 holders, $18.1bn
Q3 202233 holders, $13.7bn22 holders, $18.4bn
Q4 202232 holders, $13.4bn28 holders, $18.4bn
Q1 202325 holders, $13.6bn26 holders, $21.4bn
Q2 202330 holders, $15.2bn27 holders, $24.7bn
Q3 202328 holders, $13.1bn33 holders, $24.3bn
Q4 202324 holders, $12.7bn32 holders, $28.6bn
Q1 202419 holders, $12.8bn31 holders, $29.8bn
Q2 202426 holders, $11.2bn29 holders, $33.4bn
Q3 202430 holders, $13.9bn27 holders, $33.5bn
Q4 202433 holders, $11.5bn26 holders, $28.5bn
Q1 202527 holders, $13.8bn21 holders, $35.4bn
Q2 202530 holders, $13.3bn21 holders, $32.3bn
Q3 202525 holders, $13.6bn22 holders, $25.9bn
Q4 202527 holders, $14.9bn26 holders, $31.8bn
Q1 202624 holders, $14.3bn25 holders, $31.8bn
Q2 202629 holders, $12.8bn26 holders, $34.6bn
MDT

Medtronic PLC

Holders
24
Reported value
$12.7bn
Buyers
9
Sellers
17

Breadth -8 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 41 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MDT (9)

Arrowstreet Capital LP, Baillie Gifford & Co, Dodge & Cox, ExodusPoint Capital Management LP, First Eagle Investment Management LLC, Holocene Advisors LP, Point72 Asset Management LP, Polen Capital Management LLC, Squarepoint Ops LLC

Only VRTX (17)

Acadian Asset Management LLC, ARK Investment Management LLC, Bridgewater Associates LP, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Farallon Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Marshall Wace LLP, Maverick Capital Ltd, Neuberger Berman Group LLC, PDT Partners LLC, Tudor Investment Corp, Two Sigma Investments LP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →